TuHURA Biosciences, Inc./NV (HURA) stock
Close on Nov 11, 2026Market cap $96.86MP/E –Yield –
TuHURA Biosciences, Inc./NV reported revenue of $0 for fiscal 2025. Free cash flow was -$29.90M. At the latest close the market valued the company at $96.86M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $96.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.24
- Dividend yield
- –
- Free cash flow yield
- -30.87%
Fundamentals
- Revenue
- $0
- Net income
- -$30.62M
- EPS, diluted
- -$0.54
- Free cash flow
- -$29.90M
- Book value per share
- $0.29
- Diluted shares
- 64M
Trading
- Next earnings
- Nov 13, 2026 (estimated, before the open)
- Previous close
- $1.51
- Open
- $1.60
- Day's range
- $1.48 – $1.63
- Volume
- 494,618
- Average volume (20 days)
- 477,092
- Beta (5 years)
- 1.06
- 52-week range
- $0.41 – $3.43
- RSI (14 days)
- 35.9
- Volatility (1 year)
- 131.5%
- Relative volume
- 1.66×
- WACC
- 10.2%
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HURA | S&P 500 | Difference | HURA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.4% | -2.4% | −20.0 pts | ||
| 3 months | -33.9% | -1.2% | −32.8 pts | ||
| Year to date | +100.9% | +12.3% | +88.6 pts | ||
| 1 year | -36.1% | +12.4% | −48.6 pts | ||
| 3 years | -88.7% | +78.8% | −167.5 pts | -51.6% | +21.4% |
| 5 years | -99.9% | +75.2% | −175.1 pts | -75.1% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -66.0% | +15.2% |
Thirteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases TuHURA Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- News
About TuHURA Biosciences
Pharmaceutical Preparations
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on developing therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company’s pipeline utilizes three core technologies: the proprietary Immune Fx (IFx) platform, VISTA-inhibiting monoclonal antibodies, and Delta Opioid Receptor (DOR) targeting antibody-drug conjugates. Its lead candidate, IFx-2.0, is designed to stimulate innate immune responses against tumors and is in clinical testing as an adjunctive treatment for advanced Merkel cell carcinoma. Additional assets include TBS-2025 for acute myeloid leukemia and bi-functional antibody-drug conjugates targeting immunosuppressive myeloid-derived suppressor cells. Target end users are cancer patients with refractory disease or unmet therapeutic needs.
Company profile, executives and historyTuHURA Biosciences stock: common questions
What is TuHURA Biosciences's stock price?
HURA closed at $1.52 on Nov 11, 2026, up 0.66% on the day. Over the past 52 weeks it traded between $0.41 and $3.43.
What is TuHURA Biosciences's market cap?
TuHURA Biosciences was worth $96.86M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HURA's P/E ratio?
TuHURA Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.54), so it has no meaningful P/E ratio.
How much revenue does TuHURA Biosciences make?
TuHURA Biosciences reported revenue of $0 for fiscal 2025.
Does TuHURA Biosciences pay a dividend?
No. TuHURA Biosciences has not paid a cash dividend over the last twelve months.
When does TuHURA Biosciences report earnings next?
TuHURA Biosciences is expected to report Q3 FY2026 results on Nov 13, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has HURA stock performed over the past year?
Including dividends, HURA returned -36.1% over the past year, against +12.4% for the S&P 500.
How many HURA shares are sold short?
6M shares were sold short at the latest FINRA report, 10.24% of the float, or 12.6 days of average trading volume.
Who are TuHURA Biosciences's competitors?
Companies most similar to TuHURA Biosciences by business, industry and size include NXTC, CNTX, PHIO, GTBP, BOLT.
See a number that looks wrong?